- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05962216
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders (ReSD)
July 18, 2023 updated by: Dr. Albert Kar-Kin Chung
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders: a Naturalistic Non-interventional Prospective Follow-up Study
Not only being the mainstay of treatment for schizophrenia spectrum psychotic disorders, antipsychotics, especially the second-generation antipsychotics (SGAs) have also been recommended as augmenting agents for treating depression.
Dopaminergic agents, including both dopamine D2/D3 antagonists and dopamine partial D2 agonists, have been effective for treating psychosis and schizophrenia.
Amongst all SGAs, those with partial D2 agonistic property are generally acknowledged to have better side-effect profiles with lower incidence of extrapyramidal side-effects, prolactin increase, weight gain, QTc prolongation, and metabolic syndrome, as well as more efficacious in alleviating depressive symptoms.
Up-to-date, three SGAs, namely aripiprazole, brexpiprazole and cariprazine, are known to possess such partial D2 agonism.
ReSD-HK study is part of the ReSD Asian Study aiming to carefully evaluate a cohort of patients prescribed with brexpiprazole on its efficacy and tolerability as treatment for schizophrenia and/or depression in a real-life clinical setting.
Study Overview
Detailed Description
This is a 6-month, non-interventional, prospective naturalist study that adult patients (18-65 years old) receiving brexpiprazole for treatment of psychosis and/or as adjunctive treatment for major depressive disorder are eligible to participate.
Minimal exclusion criteria are employed to fit the usual real-life setting.
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Albert KK Chung, MBBS
- Phone Number: 2255 4486
- Email: Chungkka@hku.hk
Study Locations
-
-
-
Hong Kong, Hong Kong, 000000
- Recruiting
- Queen Mary Hospital
-
Contact:
- Albert KK Chung
- Phone Number: 2255 4486
- Email: chungkka@hku.hk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
Subjects suffering from psychosis or depressive disorders who are treated with the oral medication, brexpiprazole
Description
Inclusion Criteria:
- Age: 18- 65 years old at the time of enrollment
- Able to read and communicate in English and/or Chinese
- Able to give informed consent
- Has been diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), or International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) to have either Psychotic Disorders (F10-F19.5, F20-23, F25, F32-F33)
- is receiving brexpiprazole as treatment for less than 4 weeks at the time of recruitment
Exclusion Criteria:
- Age <18 years old
- Unable to read English or Chinese
- Unable to give informed consent
- Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Brief Psychiatric Rating Scale-24 in 6 months
Time Frame: 6 months
|
Efficacy measures the change from baseline, to that at 3rd and 6th months
|
6 months
|
Change in Clinical Global Impression in 6 months
Time Frame: 6 months
|
Efficacy measures the change from baseline, to that at 3rd and 6th months
|
6 months
|
Change in Beck Anxiety Inventory in 6 months
Time Frame: 6 months
|
Efficacy measures the change from baseline, to that at 3rd and 6th months
|
6 months
|
Change in Beck Depression Inventory in 6 months
Time Frame: 6 months
|
Efficacy measures the change from baseline, to that at 3rd and 6th months
|
6 months
|
Change in Digital Symbol Substitution Test in 6 months
Time Frame: 6 months
|
Efficacy measures the change from baseline, to that at 3rd and 6th months
|
6 months
|
Change in World Health Organization Disability Assessment Schedule 2.0 in 6 months
Time Frame: 6 months
|
Efficacy measures the change from baseline, to that at 3rd and 6th months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glasgow Antipsychotic Side-effects Scale in 6 months
Time Frame: 6 months
|
Tolerability measures at baseline, at 3rd and 6th months.
Higher score means greater side-effects with the minimum score of 0 and the maximum score of 63.
|
6 months
|
Simpson-Angus Scale in 6 months
Time Frame: 6 months
|
Tolerability measures at baseline, at 3rd and 6th months.
The cut-off score is 3.
|
6 months
|
Barnes Akathisia Rating Scale in 6 months
Time Frame: 6 months
|
Tolerability measures at baseline, at 3rd and 6th months.
The cut-off score is 2.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QTc interval
Time Frame: 6 months
|
Tolerability measures at baseline and 6th months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2023
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
July 3, 2023
First Submitted That Met QC Criteria
July 18, 2023
First Posted (Actual)
July 27, 2023
Study Record Updates
Last Update Posted (Actual)
July 27, 2023
Last Update Submitted That Met QC Criteria
July 18, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ReSD-HK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
To be shared within the ReSD Asian Study Group
IPD Sharing Time Frame
Five year after the study period upon the last subject recruitments in the respective study sites.
IPD Sharing Access Criteria
For those named investigator who are engaged in the ReSD Asian Study with agreement signed.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
Clinical Trials on Brexpiprazole
-
Otsuka Pharmaceutical Co., Ltd.Withdrawn
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAcute SchizophreniaKorea, Republic of, United States, Serbia, Ukraine, Romania, Poland, Canada, Latvia, Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedHealthy Adult MaleJapan
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.Terminated
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/STerminated
-
Otsuka Pharmaceutical Co., Ltd.Recruiting
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedNervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's TypeFrance, United States, Bulgaria, Slovenia, United Kingdom, Russian Federation, Ukraine, Finland, Canada
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedIrritability Associated With Autism Spectrum Disorder (ASD)United States